Drugs Made In Net Income
| DMII Stock | 9.98 0.03 0.30% |
As of the 22nd of February, Drugs Made shows the Mean Deviation of 0.0965, coefficient of variation of 774.43, and Standard Deviation of 0.1452. Drugs Made In technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Drugs Made's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Drugs Made's valuation are provided below:Drugs Made In does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. The current Net Loss is estimated to decrease to -0.0023. Drugs Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Drugs Made is extremely important. It helps to project a fair market value of Drugs Stock properly, considering its historical fundamentals such as Net Income. Since Drugs Made's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Drugs Made's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Drugs Made's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Diversified Capital Markets market expansion? Will Drugs introduce new products? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Drugs Made listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Drugs Made In's market price often diverges from its book value, the accounting figure shown on Drugs's balance sheet. Smart investors calculate Drugs Made's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Drugs Made's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Drugs Made's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Drugs Made 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Drugs Made's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Drugs Made.
| 11/24/2025 |
| 02/22/2026 |
If you would invest 0.00 in Drugs Made on November 24, 2025 and sell it all today you would earn a total of 0.00 from holding Drugs Made In or generate 0.0% return on investment in Drugs Made over 90 days. Drugs Made is related to or competes with GigCapital7 Corp, Diamond Hill, M3 Brigade, Axiom Intelligence, and Trailblazer Acquisition. Drugs Made is entity of United States. It is traded as Stock on NASDAQ exchange. More
Drugs Made Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Drugs Made's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Drugs Made In upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 0.1812 | |||
| Information Ratio | (0.43) | |||
| Maximum Drawdown | 0.9098 | |||
| Value At Risk | (0.20) | |||
| Potential Upside | 0.3036 |
Drugs Made Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Drugs Made's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Drugs Made's standard deviation. In reality, there are many statistical measures that can use Drugs Made historical prices to predict the future Drugs Made's volatility.| Risk Adjusted Performance | 0.056 | |||
| Jensen Alpha | 0.0113 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | (0.34) | |||
| Treynor Ratio | (0.24) |
Drugs Made February 22, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.056 | |||
| Market Risk Adjusted Performance | (0.23) | |||
| Mean Deviation | 0.0965 | |||
| Downside Deviation | 0.1812 | |||
| Coefficient Of Variation | 774.43 | |||
| Standard Deviation | 0.1452 | |||
| Variance | 0.0211 | |||
| Information Ratio | (0.43) | |||
| Jensen Alpha | 0.0113 | |||
| Total Risk Alpha | (0) | |||
| Sortino Ratio | (0.34) | |||
| Treynor Ratio | (0.24) | |||
| Maximum Drawdown | 0.9098 | |||
| Value At Risk | (0.20) | |||
| Potential Upside | 0.3036 | |||
| Downside Variance | 0.0328 | |||
| Semi Variance | (0.01) | |||
| Expected Short fall | (0.17) | |||
| Skewness | 0.5398 | |||
| Kurtosis | 3.22 |
Drugs Made In Backtested Returns
Drugs Made is very steady at the moment. Drugs Made In secures Sharpe Ratio (or Efficiency) of 0.13, which denotes the company had a 0.13 % return per unit of risk over the last 3 months. We have found twenty-six technical indicators for Drugs Made In, which you can use to evaluate the volatility of the firm. Please confirm Drugs Made's Mean Deviation of 0.0965, standard deviation of 0.1452, and Coefficient Of Variation of 774.43 to check if the risk estimate we provide is consistent with the expected return of 0.0184%. Drugs Made has a performance score of 10 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0358, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Drugs Made are expected to decrease at a much lower rate. During the bear market, Drugs Made is likely to outperform the market. Drugs Made In right now shows a risk of 0.14%. Please confirm Drugs Made In expected short fall, and the relationship between the value at risk and day median price , to decide if Drugs Made In will be following its price patterns.
Auto-correlation | 0.58 |
Modest predictability
Drugs Made In has modest predictability. Overlapping area represents the amount of predictability between Drugs Made time series from 24th of November 2025 to 8th of January 2026 and 8th of January 2026 to 22nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Drugs Made In price movement. The serial correlation of 0.58 indicates that roughly 58.0% of current Drugs Made price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.58 | |
| Spearman Rank Test | 0.7 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Drugs Made In reported net income of 0.0. This is 100.0% lower than that of the Capital Markets sector and 100.0% lower than that of the Financials industry. The net income for all United States stocks is 100.0% higher than that of the company.
Drugs Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Drugs Made's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Drugs Made could also be used in its relative valuation, which is a method of valuing Drugs Made by comparing valuation metrics of similar companies.Drugs Made is currently under evaluation in net income category among its peers.
Drugs Fundamentals
| Current Valuation | 655.39 M | ||||
| Shares Outstanding | 65.58 M | ||||
| Shares Owned By Insiders | 17.63 % | ||||
| Shares Owned By Institutions | 23.45 % | ||||
| Number Of Shares Shorted | 85.98 K | ||||
| Book Value Per Share | (0.26) X | ||||
| Short Ratio | 1.00 X | ||||
| Market Capitalization | 655.09 M |
About Drugs Made Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Drugs Made In's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Drugs Made using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Drugs Made In based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is there potential for Diversified Capital Markets market expansion? Will Drugs introduce new products? Factors like these will boost the valuation of Drugs Made. Projected growth potential of Drugs fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Drugs Made listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Drugs Made In's market price often diverges from its book value, the accounting figure shown on Drugs's balance sheet. Smart investors calculate Drugs Made's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Drugs Made's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Drugs Made's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Drugs Made should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Drugs Made's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.